Immuneering Corp
$2.26
(as of Jun 17, 9:49 AM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Immuneering Corp
Stock Price
$2.26
Ticker Symbol
IMRX
Exchange
NASDAQ
Industry Information for Immuneering Corp
Sector
Healthcare
Industry
Biotechnology
Company Description for Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Fundamentals for Immuneering Corp
Market Capitalization
$68,372,832
EBITDA
$-63,850,176
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.97
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
35,985,700
Percent Owned by Insiders
24.00%
Percent Owned by Institutions
12.58%
52-Week High
52-Week Low
Technical Indicators for Immuneering Corp
Analyst Ratings for Immuneering Corp
Strong Buy
2
Buy
2
Hold
1
Sell
0
Strong Sell
0
News About Immuneering Corp
Jun 17, 2025, 7:58 AM EST
Investing.com -- Immuneering Corporation (NASDAQ:IMRX) stock rose 7% on Monday after the clinical-stage oncology company reported positive survival data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.
See more.
Jun 17, 2025, 6:29 AM EST
(RTTNews) - Immuneering (IMRX) announced positive data from ongoing Phase 2a clinical trial evaluating atebimetinib, an oral, once-daily MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. See more.
Jun 17, 2025, 6:00 AM EST
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached -
See more.
Jun 16, 2025, 8:00 AM EST
CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. See more.